Abstract:Abstract Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer fatalities worldwide, with chronic hepatitis B infection accounting for 60% of cases. In the majority of new diagnoses, primary tumor size contraindicates surgical resection, limiting available treatment options to rarely-curative interventions that generally have severe side effects. Overall, advanced HCC is largely incurable, with a five year survival rate of <5%. To expand the treatment pipeline, we conducted a high-throughput screening campaign of our 85,000-compound small molecule library to identify agents that would exhibit selective cytotoxicity for HCC-derived cell lines, as compared to immortalized non-transformed human hepatocytes. A disubstituted aminothiazole, termed HBF-0079, emerged as a potent and selective inhibitor of cell growth and viability in the HCC lines Huh7, Hep3b, HepaRG, MHCC97H and MHCC97L, and the hepatoblastoma line HepG2, with EC50 values from 0.7 to 33 μM. Conversely, growth and viability in the non-tumorigenic hepatocyte lines THLE2 and PH5CH, and several other non-HCC cancer lines, showed only moderate to no sensitivity. Subsequent structure-activity relationship studies have identified relevant features of the molecule, and resulted in two compounds that retain selectivity and improve EC50 to < 0.1 μM in Huh7. In a murine xenograft model, growth of Hep3B-derived tumors was significantly delayed by either systemic or intratumoral administration of HBF-0079. As determined in cell culture withdrawal experiments, incubation of Huh7 cells with HBF-0079 resulted in irreversible onset of growth arrest and apoptosis. Cell cycle analysis indicated arrest in G1/G0, with subsequent entry of cells into a sub-G0 population consistent with apoptotic cell death. While a putative molecular target is currently being confirmed, we have determined that treated Huh7 cells undergo loss of AKT phosphorylation at the mTORC2-targeted residue S473, with subsequent loss of phosphorylation of the mTORC1 targets SK6 and 4EBP1; these observations are consistent with cell cycle arrest and onset of apoptosis, ostensibly through loss of AKT survival signaling and global translational shutoff. Conversely, phosphorylation of Akt or mTORC1 targets is not affected in the non-sensitive PH5CH line. Thus, we have identified a cytotoxic molecule with in vitro selectivity for liver-derived cancer cells. In vivo efficacy studies and chemical hit-to-lead optimization are currently ongoing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C68.

Itraconazole halts hepatocellular carcinoma progression by modulating sonic hedgehog signaling in rats: A novel therapeutic approach

Hedgehog signaling is a promising target for the treatment of hepatic fibrogenesis: a new management strategy using itraconazole-loaded nanoparticles

Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways

Itraconazole inhibits the Hedgehog signaling pathway thereby inducing autophagy-mediated apoptosis of colon cancer cells

Hedgehog signaling mastery: R51211's promise in augmenting the therapeutic efficacy of sorafenib

Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling

Anti-proliferation of breast cancer cells with itraconazole: Hedgehog pathway inhibition induces apoptosis and autophagic cell death

Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via suppressing Hedgehog pathway

Itraconazole Inhibits the Growth of Cutaneous Squamous Cell Carcinoma by Targeting HMGCS1/ACSL4 Axis

Unlocking vinpocetine's oncostatic potential in early-stage hepatocellular carcinoma: A new approach to oncogenic modulation by a nootropic drug

The Aryl Hydrocarbon Receptor Ligand ITE Inhibits Cell Proliferation and Migration and Enhances Sensitivity to Drug-Resistance in Hepatocellular Carcinoma.

Itraconazole Induces Apoptosis and Cell Cycle Arrest Via Inhibiting Hedgehog Signaling in Gastric Cancer Cells

Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways.

Itraconazole Exerts Its Antitumor Effect in Esophageal Cancer By Suppressing the HER2/AKT Signaling Pathway

Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy

Abstract C68: Suppression of AKT/mTOR Antiapoptotic Signaling by a Novel Drug Candidate Results in Growth Arrest and Apoptosis of Hepatocellular Carcinoma-Derived Cell Lines.

Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways

The Anti-Hepatocellular Carcinoma Cell Activity by a Novel Mtor Kinase Inhibitor CZ415

STA-9090 in combination with a statin exerts enhanced protective effects in rats fed a high-fat diet and exposed to diethylnitrosamine and thioacetamide

Polymeric Nanoparticle-Encapsulated Hedgehog Pathway Inhibitor Hpi-1 (nanohhi) Inhibits Systemic Metastases in an Orthotopic Model of Human Hepatocellular Carcinoma

Suppression Of Akt Anti-Apoptotic Signaling By A Novel Drug Candidate Results In Growth Arrest And Apoptosis Of Hepatocellular Carcinoma Cells